Dysregulated metabolism in both tumor and adjacent tissues can lead to immunosuppression, contributing to cancer progression. This metabolic imbalance hampers the immune system's ability to fight tumors effectively.
Aldometanib, a glucose starvation mimetic, has shown promising results in overcoming immune barriers in mouse models of hepatocellular carcinoma (HCC). By mimicking glucose deprivation, aldometanib helps reverse the immunosuppressive environment around the tumor.
"Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages."
Targeting tumor metabolism with glucose starvation mimetics like aldometanib can effectively reinstate immune responses, enabling longer survival in HCC-affected mice.